<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; HTA</title>
	<atom:link href="http://www.tapanray.in/tag/hta/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Neutralize Covid-19 Impact on Drug Prices And Market Access For Faster Recovery</title>
		<link>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery</link>
		<comments>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/#comments</comments>
		<pubDate>Mon, 14 Sep 2020 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fair]]></category>
		<category><![CDATA[fair drug pricing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[neutralize]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[spending]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10259</guid>
		<description><![CDATA[Covid-19 pandemic that has not spared any facet of human lives and livelihoods, has also reignited several ongoing debates related to the drug industry. The need to urgently resolve these issues grows manifold, as the real magnitude of this health &#8230; <a href="http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Policy Execution Gap Limits Access To Affordable Medicines?</title>
		<link>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-policy-execution-gap-limits-access-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/#comments</comments>
		<pubDate>Mon, 15 Oct 2018 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2001]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[declaration]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[execution]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9215</guid>
		<description><![CDATA[“The cost of new drugs is putting increasing pressure on people in both rich and poor countries”- was eloquently expressed in an article, titled “Why do new medicines cost so much, and what can we do about it?”. This was &#8230; <a href="http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing in India: 10 Chain Events to Catalyze a Paradigm Shift</title>
		<link>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift</link>
		<comments>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/#comments</comments>
		<pubDate>Mon, 17 Jun 2013 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alibaba]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[cocoon]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[composite]]></category>
		<category><![CDATA[Cosmetic]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[differentiated]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[faster]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herald]]></category>
		<category><![CDATA[Heralding]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[ICICI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Lombard]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mediclaim]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of pharma]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmacy-economics]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[remedies]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transition]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[well]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2454</guid>
		<description><![CDATA[In the matured markets of the world pharmaceutical marketing is quite different in many respect as compared to India. Besides doctors, different sets of customer groups like, healthcare providers, patient advocacy groups, pharmacy benefit managers, clinical assessment authorities play various &#8230; <a href="http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either</title>
		<link>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either</link>
		<comments>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lamy]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[lucrative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[opposition]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[Pascal]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2267</guid>
		<description><![CDATA[The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter &#8230; <a href="http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The concept of ‘Value Based Pricing (VBP)’ gaining ground to reduce cost of healthcare and improve access…but India is quite different</title>
		<link>http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different</link>
		<comments>http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/#comments</comments>
		<pubDate>Mon, 13 Dec 2010 01:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Concept]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[different]]></category>
		<category><![CDATA[gaining]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[patent patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[quite]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reduce]]></category>
		<category><![CDATA[reference]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=335</guid>
		<description><![CDATA[So far as the pharmaceutical pricing and increasing access to healthcare are concerned, year 2010 perhaps will be remembered as one of the very significant years, at least, in the recent times. In this year with new healthcare reform, President &#8230; <a href="http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
